345 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
treatment development
Develop innovative treatments to eliminate cancer death in children
3 assets undergoing pre-clinical assessment
1 asset
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
to Taxes and Estates and Gifts dated November 24, 1978 (as further amended), a transfer of debt securities by gift or by reason of the death of a U.S. holder … was not domiciled in France at the time of making the gift or at the time of his or her death and the debt securities were not used or held for use
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
or agent becomes vacant by reason of death, resignation, retirement, disqualification, removal from office or otherwise, the Board of Directors may … or certificates shall cease to be such officer or officers of the Company, whether because of death, resignation, retirement, disqualification, removal
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
to eliminate cancer death in children
3 assets undergoing pre-clinical assessment
First pediatric patient dosed with 1 clinical asset in a clinical
6-K
EX-99.5
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
this neglected disease its name, and ultimately, death.
Dietmar Berger, MD, PhD
Head of Development and Chief Medical Officer, Sanofi
“The CHMP’s positive
6-K
EX-99.3
seqns7m 4tl8
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
d8tr 8xz1
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
eqrozege7gwhp53kx2bz
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
86e37 7qe
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
11-K
s22jtjonpi
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
nkuhd nymebbe
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.2
xxfn0pt658
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
homksmbc
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
11-K
759rwlsovgjvmy45m
29 Jun 22
Annual report of employee stock purchases
11:48am
11-K
g5m98g4mfs
29 Jun 22
Annual report of employee stock purchases
11:46am
6-K
EX-99.3
o0olh
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.2
me1 whtt2
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
S-8
EX-4.1
9tlmhjjr l5oxjkmj
18 May 22
Registration of securities for employees
3:48pm
6-K
EX-99.2
ja84k5lxf0lxr5
17 May 22
Current report (foreign)
3:20pm
6-K
EX-99.1
7t58ildzw
19 Apr 22
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
11:32am